Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2020

View Archived Issues

C12orf49 is new lipid metabolism gene

Simultaneous dual base editing

Dual JAK1/TYK2 inhibitor TLL-018 shows dose-dependent anti-inflammatory activity in arthritis models

Phase I data presented for URAT1 inhibitor D-0120

FDA clears IND application for PTX-35

BeyondSpring presents positive data from PROTECTIVE-2 study of plinabulin plus Neulasta

First patient dosed in phase Ib study of RMC-4630 in combination with AMG-510

First-in-human data for MGD-013 in unresectable or metastatic neoplasms

HX-008 plus irinotecan show promising activity in advanced gastric adenocarcinoma

TV technology wants to be brain delivery's all-terrain vehicle

Loss-of-function mutations in JAM2 gene cause familial brain calcification

Phase I study finds manageable toxicity with LY-2880070 alone and with gemcitabine

Black Belt TX patents arginase inhibitors

Taisho Pharmaceutical discloses new antibacterials

Grey Wolf Therapeutics synthesizes ERAP1 inhibitors

Merck & Co. describes new adenosine A2A and/or A2B receptor antagonists

Opthea reports phase IIa topline data on OPT-302 for refractory DME

Bacainn announces phase I study initiation for ulcerative colitis candidate BT-051

NLRP3 inhibitors presented by Novartis Inflammasome Research

Wharton's jelly-derived mesenchymal stem cells effective in graft-versus-host disease trial

FDA allows phase III protocol for SPI-1005 for Meniere's disease

Fulcrum submits IND for phase III study of losmapimod for COVID-19

Pfizer reports topline data from JADE TEEN trial of abrocitinib in adolescent atopic dermatitis

NFlection initiates phase IIa study of NFX-179 gel for cutaneous NF-1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
SKL-35501 shows broad antitumor activity in solid tumors
BioWorld Science
Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic...